CD19 specific chimeric antigen receptor and uses thereof
The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells expressing 4G7-CAR at their surface which confers a prolonged “activated” state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.
1. A CD19 specific chimeric antigen receptor (CAR), wherein the CAR comprises the amino acid sequence of SEQ ID NO: 15.
2. The CD19 specific CAR of claim 1 , wherein the CAR is bispecific.
3. The CD19 specific CAR of claim 1 , wherein the CAR is expressed on the surface of a T-cell as part of an allogeneic immunotherapy treatment for cancer expressing CD19.
4. A polynucleotide encoding the CD19 specific CAR of claim 1 .
5. An expression vector comprising the polynucleotide of claim 4 .
6. An isolated T cell expressing the CD19 specific CAR of claim 1 , wherein said T cell is a cytotoxic T lymphocyte (CTL).
7. A method of engineering an immune cell to express the CD19 specific CAR of claim 1 , said method comprising introducing into an immune cell a polynucleotide encoding said CAR.
8. The method of claim 7 , wherein said immune cell is a CTL.
9. A method of treating cancer in a subject, said method comprising administering to a subject having cancer expressing CD19 the T cell of claim 6 .
10. The method of claim 9 , wherein said cancer is a B-cell lymphoma or leukemia.
11. The method of claim 9 , wherein said T cell administered to the subject is an allogeneic T cell.